Cargando…
NO and hepatocellular cancer
NO has broad and sometimes dichotomous roles in cancer. The effects of NO in tumours depend on the type and localization of NOS isoforms, concentration and duration of NO exposure, and cellular sensitivity to NO. Hepatocellular carcinoma (HCC) is a common and lethal disease for which no effective th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707086/ https://www.ncbi.nlm.nih.gov/pubmed/31423564 http://dx.doi.org/10.1111/bph.14838 |
_version_ | 1783617276220538880 |
---|---|
author | Wang, Ronghua Geller, David A. Wink, David A. Cheng, Bin Billiar, Timothy R. |
author_facet | Wang, Ronghua Geller, David A. Wink, David A. Cheng, Bin Billiar, Timothy R. |
author_sort | Wang, Ronghua |
collection | PubMed |
description | NO has broad and sometimes dichotomous roles in cancer. The effects of NO in tumours depend on the type and localization of NOS isoforms, concentration and duration of NO exposure, and cellular sensitivity to NO. Hepatocellular carcinoma (HCC) is a common and lethal disease for which no effective therapy other than surgical resection exists. Over two decades of research has yielded evidence that NO generated by the inducible NOS (iNOS or NOS2) contributes to HCC progression in at least a subset of patients with HCC. The co‐expression of iNOS with COX‐2 may portend a particularly aggressive cancer phenotype in HCC and at the same time reveal an opportunity for pharmacological intervention. In this review, we focus on what is known about the influence of NO in HCC neoplastic transformation, proliferation and apoptosis, angiogenesis, invasion, and metastasis, cancer stem cells, and the host immune response against the tumour. We discuss the implications of recent findings for targeting the NO pathways in HCC. |
format | Online Article Text |
id | pubmed-7707086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77070862020-12-09 NO and hepatocellular cancer Wang, Ronghua Geller, David A. Wink, David A. Cheng, Bin Billiar, Timothy R. Br J Pharmacol TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY NO has broad and sometimes dichotomous roles in cancer. The effects of NO in tumours depend on the type and localization of NOS isoforms, concentration and duration of NO exposure, and cellular sensitivity to NO. Hepatocellular carcinoma (HCC) is a common and lethal disease for which no effective therapy other than surgical resection exists. Over two decades of research has yielded evidence that NO generated by the inducible NOS (iNOS or NOS2) contributes to HCC progression in at least a subset of patients with HCC. The co‐expression of iNOS with COX‐2 may portend a particularly aggressive cancer phenotype in HCC and at the same time reveal an opportunity for pharmacological intervention. In this review, we focus on what is known about the influence of NO in HCC neoplastic transformation, proliferation and apoptosis, angiogenesis, invasion, and metastasis, cancer stem cells, and the host immune response against the tumour. We discuss the implications of recent findings for targeting the NO pathways in HCC. John Wiley and Sons Inc. 2019-12-11 2020-12 /pmc/articles/PMC7707086/ /pubmed/31423564 http://dx.doi.org/10.1111/bph.14838 Text en © 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY Wang, Ronghua Geller, David A. Wink, David A. Cheng, Bin Billiar, Timothy R. NO and hepatocellular cancer |
title | NO and hepatocellular cancer |
title_full | NO and hepatocellular cancer |
title_fullStr | NO and hepatocellular cancer |
title_full_unstemmed | NO and hepatocellular cancer |
title_short | NO and hepatocellular cancer |
title_sort | no and hepatocellular cancer |
topic | TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707086/ https://www.ncbi.nlm.nih.gov/pubmed/31423564 http://dx.doi.org/10.1111/bph.14838 |
work_keys_str_mv | AT wangronghua noandhepatocellularcancer AT gellerdavida noandhepatocellularcancer AT winkdavida noandhepatocellularcancer AT chengbin noandhepatocellularcancer AT billiartimothyr noandhepatocellularcancer |